ACE-1334

N/A

Report date: 2022/12/19 20:00:27

Base Information

Drug NameACE-1334
Drug Alias NameACE-1334MK-2225
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionTransforming growth factor beta inhibitors
TargetsTransforming growth factor beta
Therapy Area/IndicationsScleroderma, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAcceleron Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme LLC
Inactive CompaniesN/A
Active IndicationsScleroderma, Systemic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A